抗BCMA联合抗CD19 CAR-T细胞治疗复发/难治多发性骨髓瘤:单臂Ⅱ期临床试验

Comments on "A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma:a single-arm,phase 2 trial"

本文最初发表于2019年Lancet Hematology,文章题录为:Yan Z,Cao J,Cheng H,et al.A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma:a single-arm,phase 2 trial[J].Lancet Haematol,2019,6:e521-e529。该研究表明,联合输注人源化抗CD19及鼠源抗BCMA CAR-T细胞在治疗复发/难治多发性骨髓瘤(R/R MM)显示出了肯定的疗效,且其安全性良好。这是一个有前景的治疗策略,值得临床试用。这一研究结果为R/R MM的细胞免疫治疗提供了新的思路。